Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) – how are clinical trials affected?
- 21 January 2020
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (2) , 93-97
Abstract
Effectiveness of lifestyle interventions in NALFD (non-alcoholic fatty liver disease) – how are clinical trials affected?. Expert Opinion on Investigational Drugs. Accepted 12 January 2020.Keywords
This publication has 12 references indexed in Scilit:
- The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat contentJournal of Hepatology, 2019
- Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise programAlimentary Pharmacology & Therapeutics, 2019
- Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver diseaseJournal of Hepatology, 2018
- Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2018
- High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistanceJournal of Hepatology, 2018
- Treatment of NAFLD with diet, physical activity and exerciseJournal of Hepatology, 2017
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic SteatohepatitisGastroenterology, 2015
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialThe Lancet, 2015
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 DiabetesNew England Journal of Medicine, 2013
- Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trialThe American Journal of Clinical Nutrition, 2012